ECM
RNAC icon

Endurant Capital Management’s Cartesian Therapeutics RNAC Stock Holding History

Endurant Capital Management’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-15,110
Closed -$481K – 47
2023
Q3 		$481K Sell
15,110
-7,761
-34% -$259K 0.43% 40
2023
Q2 		$768K Sell
22,871
-49,340
-68% -$1.77M 0.67% 26
2023
Q1 		$3.01M Sell
72,211
-53,710
-43% -$2.52M 1.55% 17
2022
Q4 		$4.27M Sell
125,921
-5,359
-4% -$228K 1.73% 16
2022
Q3 		$6.46M Sell
131,280
-22,441
-15% -$1.23M 2.1% 19
2022
Q2 		$6.04M Buy
153,721
+38,656
+34% +$1.15M 2.12% 16
2022
Q1 		$4.25M Buy
115,065
+44,281
+63% +$2.77M 1.12% 24
2021
Q4 		$6.92M Buy
70,784
+36,734
+108% +$3.95M 1.67% 20
2021
Q3 		$4.25M Buy
34,050
+3,152
+10% +$381K 0.97% 28
2021
Q2 		$3.88M Buy
30,898
+508
+2% +$60.5K 1.07% 36
2021
Q1 		$4.13M Sell
30,390
-2,629
-8% -$326K 1.08% 35
2020
Q4 		$3M Sell
33,019
-17,383
-34% -$1.51M 1.08% 32
2020
Q3 		$3.75M Sell
50,402
-8,909
-15% -$683K 1.11% 30
2020
Q2 		$5.05M Buy
59,311
+50,801
+597% +$4.6M 0.28% 22
2020
Q1 		$615K Buy
8,510
+7,650
+890% +$739K 0.28% 41
2019
Q4 		$61K Buy
+860
New +$41.5K 0.02% 54

Other funds holding RNAC

AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Endurant Capital Management's RNAC Position: Q4 2023 in Review

Endurant Capital Management sold out of Cartesian Therapeutics (RNAC) in Q4 2023, closing a stake of 15,110 shares — an estimated $481K sold.

Endurant Capital Management first reported a position in RNAC in Q4 2019 and held it in 16 quarters. The position peaked at $6.92M in Q4 2021. 80 funds tracked by Wall St. Rank hold RNAC as of Q4 2023.

  • Endurant Capital Management reported no remaining Cartesian Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Endurant Capital Management sold 15,110 Cartesian Therapeutics shares in Q4 2023, an estimated $481K.
  • Endurant Capital Management first reported a position in Cartesian Therapeutics in Q4 2019 and held it in 16 quarters.
  • Endurant Capital Management's Cartesian Therapeutics position peaked at $6.92M in Q4 2021.
  • 80 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q4 2023.

Based on Endurant Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.